Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | GBT021601, a next generation HbS polymerization inhibitor for the treatment of SCD

Clark Brown, MD, PhD, Aflac Cancer & Blood Disorders Center, Atlanta, GA, outlines the mechanism of action of GBT021601, a next-generation sickle hemoglobin (HbS) polymerization inhibitor developed for the treatment of sickle cell disease (SCD), highlighting the results of Phase I studies evaluating this agent. The study reported that the drug was well-tolerated and led to significantly increased hemoglobin levels. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.


Consultancy: Global Blood Therapeutics, Imara, Novartis, Novo Nordisk; Research support: Global Blood Therapeutics, Forma Therapeutics, Imara, Novartis, Pfizer